4.7 Article

Construct Validity and Minimal Important Difference of 6-Minute Walk Distance in Survivors of Acute Respiratory Failure

期刊

CHEST
卷 147, 期 5, 页码 1316-1326

出版社

ELSEVIER
DOI: 10.1378/chest.14-1808

关键词

-

资金

  1. National Heart, Lung, and Blood Institute [R24HL111895, R01HL091760, R01HL091760-02S1, R01HL096504, P050HL7399]
  2. Johns Hopkins Institute for Clinical and Translational Research [UL1TR000424-06]
  3. Albuterol to Treat Acute Lung Injury (ALTA)
  4. Early vs Delayed Enteral Feeding
  5. Omega-3 Fatty Acid/Antioxidant [HSN268200536170C, HHSN268200536171C, HHSN268200536173C, HHSN268200536174C, HSN268200536175C, HHSN268200536179C]
  6. Australian National Health and Medical Research Council (NHMRC) [352407]
  7. NHMRC [454717]
  8. Physiotherapy Research Foundation
  9. Austin Hospital Medical Research Foundation
  10. Australian and New Zealand Intensive Care Society

向作者/读者索取更多资源

OBJECTIVE: The 6-min walk distance (6MWD), a widely used test of functional capacity, has limited evidence of construct validity among patients surviving acute respiratory failure (ARF) and ARDS. The objective of this study was to examine construct validity and responsiveness and estimate minimal important difference (MID) for the 6MWD in patients surviving ARF/ARDS. METHODS: For this secondary data analysis of four international studies of adult patients surviving ARF/ARDS (N = 641), convergent and discriminant validity, known group validity, predictive validity, and responsiveness were assessed. MID was examined using anchor-and distribution-based approaches. Analyses were performed within studies and at various time points aft er hospital discharge to examine generalizability of findings. RESULTS: The 6MWD demonstrated good convergent and discriminant validity, with moderate to strong correlations with physical health measures (vertical bar r vertical bar = 0.36-0.76) and weaker correlations with mental health measures (vertical bar r vertical bar = 0.03-0.45). Known-groups validity was demonstrated by differences in 6MWD between groups with differing muscle strength and pulmonary function (all P < .01). Patients reporting improved function walked farther, supporting responsiveness. 6MWD also predicted multiple outcomes, including future mortality, hospitalization, and health-related quality of life. The 6MWD MID, a small but consistent patient-perceivable effect, was 20 to 30 m. Findings were similar for 6MWD % predicted, with an MID of 3% to 5%. CONCLUSIONS: In patients surviving ARF/ARDS, the 6MWD is a valid and responsive measure of functional capacity. The MID will facilitate planning and interpretation of future group comparison studies in this population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据